Evidence map›Paper›PMID 36964252›Full record

ArticleExperimental & molecular medicine2023

Mesenchymal stem cell-derived extracellular vesicles subvert Th17 cells by destabilizing RORγt through posttranslational modification.

Sunyoung Jung, Sunho Lee, Hyun Je Kim, Sueon Kim, Ji Hwan Moon, Hyunwoo Chung, Seong-Jun Kang, Chung-Gyu Park

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Experimental & molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Mesenchymal stem cell-derived extracellular vesicles in periodontal bone repair.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 4 countries.

Sunyoung Jung *Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, 03080, Korea.
Sunho Lee *Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, 03080, Korea.
Hyun Je Kim *Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea.
Sueon KimDepartment of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, 03080, Korea.
Ji Hwan MoonSamsung Genome Institute, Samsung Medical Center, Seoul, Korea.
Hyunwoo ChungDepartment of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, 03080, Korea.
Seong-Jun KangDepartment of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, 03080, Korea.
Chung-Gyu ParkDepartment of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, 03080, Korea. chgpark@snu.ac.kr.ORCID http://orcid.org/0000-0003-4083-8791
Seoul National University · KRSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cell (MSC)-derived small extracellular vesicles (MSC-sEVs) are known to exert immunosuppressive functions. This study showed that MSC-sEVs specifically convert T helper 17 (Th17) cells into IL-17 low-producer (ex-Th17) cells by degrading RAR-related orphan receptor γt (RORγt) at the protein level. In experimental autoimmune encephalomyelitis (EAE)-induced mice, treatment with MSC-sEVs was found to not only ameliorate clinical symptoms but also to reduce the number of Th17 cells in draining lymph nodes and the central nervous system. MSC-sEVs were found to destabilize RORγt by K63 deubiquitination and deacetylation, which was attributed to the EP300-interacting inhibitor of differentiation 3 (Eid3) contained in the MSC-sEVs. Small extracellular vesicles isolated from the Eid3 knockdown MSCs by Eid3-shRNA failed to downregulate RORγt. Moreover, forced expression of Eid3 by gene transfection was found to significantly decrease the protein level of RORγt in Th17 cells. Altogether, this study reveals the novel immunosuppressive mechanisms of MSC-sEVs, which suggests the feasibility of MSC-sEVs as an attractive therapeutic tool for curing Th17-mediated inflammatory diseases.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalExtracellular VesiclesMesenchymal Stem CellsAnimalsCell DifferentiationMiceNuclear Receptor Subfamily 1, Group F, Member 3Protein Processing, Post-TranslationalTh17 CellsNuclear Receptor Subfamily 1, Group F, Member 3

Identifiers

PMID36964252
PMCPMC10073130
OpenAlexW4360864241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.